Two major President Trump-centric events have been unfolding these past few weeks, and each has alternatingly claimed the limelight and been overshadowed by the other. First, we have the ongoing Senate impeachment hearings, which began January 16, and second, phase one of the U.S.-China trade deal, which was signed and made public on January 15.
Search Results for phase
On April 10, 2019, the Los Angeles Department of Cannabis Regulation (or “DCR”), the local department that oversees cannabis operators, sent an email blast regarding its newly re-designed website. One of the many new features is an interactive city licensing map, which breaks down each individual neighborhood in the City of Angels for retail operations.
On Friday, January 31, the Los Angeles Department of Cannabis Regulation (“DCR”) issued an updates bulletin to stakeholders via email that outlines some important highlights and reminders for licensees and would-be licensees in the City. Below are the key points, with analysis. 1. 100 Phase 3 Retail Round One applicants determined eligible for further processing. The
The City of Los Angeles is no stranger to change and struggle around its local cannabis industry. Since the passage of Proposition M back in 2017, the City has made great strides but also suffered significant setbacks in building its licensed cannabis marketplace. Even through the COVID-19 pandemic, this trend continues for Los Angeles and
It’s been a while since we’ve written about the unfolding cannabis licensing situation in the City of Los Angeles, and a lot has happened. For some background on LA’s complicated licensing process, it has proceeded to date in multiple “phases” administered by the Los Angeles Department of Cannabis Regulation (“DCR”): The first phase was limited to
I’ve written in the past about the precarious business of buying and selling existing dispensaries in Los Angeles, but that was under the now repealed Proposition D. In March of 2017, Angelenos voted in favor of Proposition M, which is a licensing and regulatory piece of legislation implemented and overseen by the City’s Department of
Efforts by the Multidisciplinary Association for Psychedelic Studies (MAPS) to legalize prescription MDMA (Ecstasy) appear to have passed a gigantic hurdle earlier this month: MDMA is on track to meet the testing requirements to be a legalized prescription drug, specifically intended to treat the symptoms of post-traumatic stress disorder (PTSD). After analyzing the preliminary results
Getting a cannabis license in Los Angeles has been notoriously difficult—and may be about to get worse as news dropped last week that a Los Angeles City Council member is recommending that the most recent phase of licensing applications essentially be suspended. For some background on LA’s complicated licensing process, it has proceeded to date
1. Manufacturing in China is Risky For many, the short answer is yes. Let me explain…. 2. U.S. Tariffs Make Manufacturing in China Risky First there are the tariffs, which come and go and come and go, but are always a risk for any company that buys product from China for sale in the United
Let’s talk about psilocybin today. Psilocybin is the naturally occurring, psychedelic ingredient found in around 200 species of mushrooms. Like cannabis, it is believed that psilocybin use by humans predates recorded history by at least a few thousand years. Also like cannabis, psilocybin has always been thought to have medical applications; and it has demonstrated